Mydriaticum (Tropicamide)

Tropicamide, the active ingredient in Mydriaticum, is an anticholinergic (muscarinic antagonist) presented as an ophthalmic solution for ocular use. It is employed to dilate the pupil and temporarily paralyze the eye's focusing ability for diagnostic examinations.

GNH USA supplies Mydriaticum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Tropicamide acts as a mydriatic and cycloplegic agent, facilitating ocular examinations and procedures.

- Induction of mydriasis for ophthalmic examination: provides rapid pupil dilation to allow thorough retinal evaluation. - Cycloplegia for diagnostic procedures: temporarily paralyzes the ciliary muscle to prevent accommodation during refraction testing. - Pre‑operative pupil dilation for intraocular surgery: ensures adequate view and access for surgeons.

Adverse reactions may occur following ocular administration of Tropicamide.

Common Side Effects: - Transient stinging or burning sensation at the application site. - Blurred vision lasting several hours. - Increased sensitivity to light (photophobia). - Mild headache.

Serious or Rare Side Effects: - Acute angle‑closure glaucoma. - Allergic eye inflammation or severe conjunctivitis. - Systemic anticholinergic effects such as dry mouth or tachycardia. - Severe ocular irritation requiring medical attention.

Prior to using Tropicamide, consider the following safety measures.

- Assess ocular history: identify narrow‑angle glaucoma or other anterior segment abnormalities. - Monitor intra‑ocular pressure: especially in patients with glaucoma risk. - Use the lowest effective dose: to achieve required dilation while minimizing exposure. - Avoid in patients with known hypersensitivity to anticholinergic eye drops. - Consider pregnancy and lactation status: use only if clearly needed. - Store at room temperature: keep in the original container, protect from light and moisture.

Tropicamide may interact with other medications affecting ocular or systemic anticholinergic activity.

Major Interactions (Avoid): - Concurrent use of other mydriatic agents (e.g., phenylephrine) may cause excessive dilation. - Systemic anticholinergics (e.g., atropine) increase risk of systemic anticholinergic effects. - Adrenergic agonists used for ocular pressure control may exacerbate intra‑ocular pressure spikes.

Moderate Interactions (Monitor Closely): - Topical ocular anesthetics: may alter absorption and effect duration. - Ocular antihistamine drops: potential additive drying of the ocular surface. - Systemic antihistamines: may increase anticholinergic burden, requiring observation.